Hoe verhoudt PRCT's PS Ratio zich tot zijn concurrenten?

PRCT is duur op basis van de Price-To-Sales -ratio ( 24.1 x) vergeleken met het gemiddelde van de peer ( 9.5 x).

Hoe verhoudt PRCT's PS Ratio zich tot andere bedrijven in de US Medical Equipment industrie?

PRCT is duur op basis van de Price-To-Sales -ratio ( 24.1 x) vergeleken met het US Medical Equipment -industriegemiddelde ( 3.2 x).

Wat is PRCT's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

PRCT is duur op basis van de Price-To-Sales Ratio ( 24.1 x) vergeleken met de geschatte Fair Price-To-Sales Ratio ( 5.4 x).

Wat is de reële prijs van PRCT als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van PRCT te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is minder dan 20 % hoger dan de huidige aandelenkoers.

PROCEPT BioRobotics (Nasdaq:PRCT) - Aandelenkoers, Nieuws & Analyse

PRCT Overzicht aandelen

PRCT fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 24.61% per jaar groeien

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

PROCEPT BioRobotics Corporation Concurrenten

Inspire Medical Systems

NYSE:INSP

US$5.2b

Axonics

NasdaqGS:AXNX

US$3.6b

TransMedics Group

NasdaqGM:TMDX

US$2.7b

Shockwave Medical

NasdaqGS:SWAV

US$12.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PROCEPT BioRobotics
Historische aandelenkoersen
Huidige aandelenkoers	US$88.94
52 Week Hoogtepunt	US$103.81
52 Week Laag	US$31.57
Bèta	1
11 maand verandering	28.99%
3 maanden verandering	36.82%
1 Jaar Verandering	169.27%
33 jaar verandering	122.29%
5 jaar verandering	n/a
Verandering sinds IPO	112.06%

Recent nieuws en updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

Rendement voor aandeelhouders

	PRCT	US Medical Equipment	US Markt
7D	-8.7%	-1.2%	-2.1%
1Y	169.3%	22.4%	29.6%

Rendement versus industrie: PRCT overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 22.4 % opleverde.

Rendement versus markt: PRCT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 29.6 %.

Prijsvolatiliteit

Is PRCT's price volatile compared to industry and market?
PRCT volatility
PRCT Average Weekly Movement	13.5%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van PRCT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 14% ) van PRCT is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	626	Reza Zadno	www.procept-biorobotics.com

PROCEPT BioRobotics Corporation, een chirurgisch robotica bedrijf, richt zich op het ontwikkelen van transformatieve oplossingen in de urologie in de Verenigde Staten en internationaal. Het bedrijf ontwikkelt, produceert en verkoopt het AquaBeam Robotic System, een beeldgestuurd chirurgisch robotsysteem voor gebruik in minimaal invasieve urologische chirurgie met de nadruk op de behandeling van goedaardige prostaathyperplasie (BPH). Het bedrijf ontwerpt ook Aquablatie-therapie voor mannen die lijden aan symptomen van de lagere urinewegen als gevolg van BPH.

PROCEPT BioRobotics Corporation Samenvatting

Hoe verhouden de winst en inkomsten van PROCEPT BioRobotics zich tot de beurswaarde?
PRCT fundamentele statistieken
Marktkapitalisatie	US$4.81b
Inkomsten(TTM)	-US$100.06m
Inkomsten(TTM)	US$199.84m

24.1x

P/S-verhouding

-48.1x

Koers/Winstverhouding

Is PRCT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PRCT resultatenrekening (TTM)
Inkomsten	US$199.84m
Kosten van inkomsten	US$85.16m
Brutowinst	US$114.68m
Overige uitgaven	US$214.74m
Inkomsten	-US$100.06m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.85
Brutomarge	57.39%
Nettowinstmarge	-50.07%
Schuld/Eigen Vermogen Verhouding	22.2%

Hoe presteerde PRCT op de lange termijn?

Bekijk historische prestaties en vergelijking

PRCT Overzicht aandelen

Beloningen

Risicoanalyse

PROCEPT BioRobotics Corporation Concurrenten

NYSE:INSP

US$5.2b

NasdaqGS:AXNX

US$3.6b

NasdaqGM:TMDX

US$2.7b

NasdaqGS:SWAV

US$12.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $174.999916 million.

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation has filed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation to Report Q3, 2024 Results on Oct 28, 2024

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $174.999916 million.

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation has filed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation to Report Q3, 2024 Results on Oct 28, 2024

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation Revises Revenue Guidance for Full Year 2024

PROCEPT BioRobotics Corporation to Report Q2, 2024 Results on Aug 01, 2024

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock